CA2134680C - Tissue-specific implantable therapeutic agent delivery system - Google Patents
Tissue-specific implantable therapeutic agent delivery system Download PDFInfo
- Publication number
- CA2134680C CA2134680C CA002134680A CA2134680A CA2134680C CA 2134680 C CA2134680 C CA 2134680C CA 002134680 A CA002134680 A CA 002134680A CA 2134680 A CA2134680 A CA 2134680A CA 2134680 C CA2134680 C CA 2134680C
- Authority
- CA
- Canada
- Prior art keywords
- agent
- biodegradable
- agents
- vasoinductive
- recited
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/915—Method or apparatus for preparing biological material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S707/00—Data processing: database and file management or data structures
- Y10S707/912—Applications of a database
- Y10S707/942—Legal/academic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S707/00—Data processing: database and file management or data structures
- Y10S707/99931—Database or file accessing
- Y10S707/99933—Query processing, i.e. searching
- Y10S707/99934—Query formulation, input preparation, or translation
Abstract
A system for tissue-specific delivery of therapeutic agents includes an implantable element biodegradable in situ within human tissue; a vasoinductive agent integrated into a surface of the element ; and having the therapeutic agents incorporated into the implantable element. The figure shows a method of construction of a tubu le in which there is a plurality of concentric, hollow tubules (e.g. 100, 200, 300). Upon implantation of the implantable element into the tissue, the vasoinductive agent stimulates capillary growth, facilitating delivery of the therapeutic agents to the selected tissue.
Description
vV~ 93/21859 . ? ~ 3 ~ ~ $ ~ Pf'I'/iJS9~/04287 TISSUE- SPECIFIC IMPI~NTABLE Th~IPEUTIC AGENT DELIVERY
SYSTEM
BACKGROUND OF THE INVEi~'TION
Biodegradable materials have been known in W~ 93/21859 PCT/U~93/04287 °'"''' ~~.3~~~0 SUMMARI OF THE TNVENTrON
A ssrstem 'for tissue-specific deliverz-of therapeutic agents includes ~an imp l.antable element biodegradable in situ within human tissue; a vasoinducti~~e agent integrated into a surface of tha element; and having the therapeutic 'agents incorporated into the implantable element.
Upan implanta ion of the implantable element ,into tissue, the vasoinductive agent stimulates capillary growth, facilitating delivery of the therapeutic agents to the selected tissue.
More, particularl~T, the present invention provides for a biodegradable substrate upon which is-applied a bioactive or pharmakinetic agent. Where a p?urality of different agents are employed,'the various agents are,applied in a matrix-like fashion upon the substrate: The ~:;- ~~ ~ substrate' is then rolled about a' major or time axis 'thereof such that, in a rro s-section taken . r. ~ ...,X
~ r .n N ,rf.. .....T. I . . T
-r: r .t. a., m. ~ , c~ ,cor..c :y .,.r .~ .
....f v, n,:nr;, ,P:Y"i... 'd'u~
.. , .. r.. -y> ~. v,,~3' .
..,...,..,.x':,.. n. f . ~. i> '5~.9.r. ..f , ~'.~' n~ . J. .., :... . , .. . , l.. .t~...
' 'f . M ~.1.~ . 1 .
,...i..;~.... ...~....a..i::,...,..W.r...~fl..f>.,,.:,.!tf..
~%~:~.....TT?~?t,.,....~fi~I:.rv....fa..:=.!!i'.La,R,.K.n..,::1~~,..x1x_....n., _ >,..n:at...v..tv~.re,.l.'Br9.rk~a..o ......,..,. ...........,...x.
N'~ 93/21859 ~ ~ ~ ~ ~ 1'CT/U~93104287 ..,,> _ radially from said axis, there may be defined a spiral cross-section. Upon the surface o.f the rolled substrate is applied-a vascular It is yet another object of the invention to provide a biodegradable implant for delivery of pharmakinetic agents, comprising:
(a) a therapeutically effective amount of a vasoinductive agent;
(b) in physical communication with said vasoinductive agent, a biodegradable element having affixed thereto at least one pharmakinetic agent, said biodegradable element comprising a series of radially concentric shells having respectively different pharmakinetic agents, or respectively different combinations of said pharmakinetic agents, disposed upon each of said respective, radially concentric shells such that the outermost shell and its associated agents will be delivered earliest while the innermost shell and its corresponding agents will be delivered last to a human tissue of interest, whereby, upon implantation of said biodegradable implant into said human tissue, said vasoinductive agent will stimulate capillary growth to thereby facilitate delivery of said pharmakinetic agents as a function of the rate of in vivo dissolution of said biodegradable element within said human tissue.
The above and yet other objects and advantages of the present invention will become apparent from the hereinafter set forth Brief Description of the Drawings, Detailed Description of the Invention and Claims appended herewith.
,:
y r ..~ . ~~..:
v .r ,. r ., k , a_ ., s .c- .~ ~ ' ~.
,,; ~,. z .. ~ , _ _.
." A
.. ~..5 .~
n: ,~w ~.. ~~ .. ° ~.
.. , ~ ~ . , .. '' .. ~ , :'" . . .. . .. ,.. . , .. W' . , :..::s... . ... ..,.~.~~T.., ~''.'~'s's'~' ,'_~~s~:~c. ~..~?,.~";x~'~..v~-..,...,~ ~V0 93/21859 PCT/tJ~93144Z~7 Fig. 6 is a cross-sectional view taken ai.ong Line 6-6 of Fig. 5.
WO 93/21859 PCTlUS93l04287 ....
Figs. l3 and l4 are views similarl~° to Fig.
'l but shok=inj other embodiments thereof.
i DETAILED DESCRIPTION OF THE INVENTION
With reference to Fig. 1 there is shown, in front perspective view, a patient 10 having scalp 20 in which have been placed incisions 12, preparatory to a hair implant procedure.
Fig. 2 is a top view of the patient 10 of Fig. 1 showing, between incisions 12, various types of hair implantation structures 14 and 16.
Such structures 14 and 16 may comprise hair follicles taken from other areas of the patient's own scalp (known as homographs), may comprise a synthetically created hair implant or may comprise a combination of homographs and synthetically created hair implants.
The insertion of the inventive biodegradable timed release implants 18 between such hair structures or normally occurring or thinning hair follicles, acts to provide required nutrition, WO 93/2859 PC~'/US931U4287 X134680 ..
i~
including amino acids; hormones o_r~drugs such 1W0 93/2159 PCT/US93/~42~7 would be particular pol~~peptides. Different poly-peptides correspond to different stakes of the i~0 93/21859 FCT/US93l04287 ~~~4sg~
spiral sl.rtacture, while the ~ele~en-related pol.~=-W~ ~3/21i359 PLTlUS~3/042~7 ..
ls' For example, it may be desirable to release the pharmakinetic agent during the categen phase -.,.~ VfO 93/2~8~9 PCT/US931442~7 '' 2~.34~8~
substrate 28 of implant 18 may also be varied.
For example, as is shown in the side cross-sectional 'riew of Fig. 7, if one wishes to increase the duration of deli~~ery of a bioactive agent 130 relative to the duration during which am agent. 131 is delivered, end 132 of substrate 128 mad= be thic'hened while end I,34 may be made narrower, this meaning that agent. 130 would be released more 'sl owl~~ into the del iverv site, while went 13I would be del ivered more quickl3:
Should''one wish tQ achieve: the reverse effect, a~ structure of the t~pe showy in Fig . 8 would 1?e 'used in which edge 232 of biodegradable substrate 228 would be narrowed while edge 234 of-thP sub-strafe ~ao.uld be thickened, thereby providing' for faster deliVer~',of agent 230 at the beginning of the biodegrading of the implant and a sl.o~aer deliver~T of agent 231 toward the end of the action of the implant.
m. ~ ;
,~ ~ : ~.
.~ . ~ .,, . .,:- ., :, ::.~
..T ,.:'9 . ~. .T
J t'...' f,'.
t ~t ., ,~~'y,:~( . rh T .gym...
. ...,1.
k~ r r.t~ .~ .'j'"L
~.i i .
. ,1'. .
~n~,., n .,. Y (~
x .
!-irv.!'~, yf',~. w ~.~~' .' 7 t , t~'., E..:
.~ . H'~~., ~ n J, t ~ .:r r' ... r ., .. fi .J- ~"~x,~, .~L.n, f . ~. c'Y
.r v. A
a ,.r ~ '~33..
.e;,: z .
,t~ ~ 3~3'..
: ,~: .
F .: .:~' , . ~ ,:.
.. a ..
:, .
x .. . ..
s. , f . N ,~
t : a #
: _ , nEJ
: ~:r ~~r 'a . r:
.
s - ::~if .. r JS
." , ~ r ..,ust. r.x.:..r..
a>T .~.
s~:-'~.
P i..
r. :,Jt:
.fit ...t.
7:....."t~
. 1.~Y7f m1 my~%~
.~u .~ a ~ .,..Td,n.-.;
n,.;.:, , , , ~ r ., i~ .
. , ,r".
, ,is .
. . . , ..r....
~_c"..:......,....
. n....t;:.i..r._.,.
,.Al<....rr~.,.>.._;1.3..v,..rl;>r.r..,.,.",....e~.".:.,~..._...>a:..~:...~.~', ,.,fr...._._.~:.-~,ti'....>;~~.,._..~,....fi,~sra..a.~~.r~:~',r~..s~:...,~s.".r.~...r....f.-i.,~.Aa.Yn.:'~'~n_i_._......
........__.........., 1~0 93/2859 PCT/US93/04287 . .
d It is noted that the rate of~...'dissolution of respective areas of substFa~te 28 may also be regulated by varying the~internal binding ,.-~~,. 1V~ 93/21859 PCflU~s93104287 structure. This provision of vasoinductive agent.
13~ alonj the time axis of the structure will '~~.3 4~~~
where a plurality of different pharmakinetic ~, VVO 9312 D X59 ~ ~ ~ ~ ~ ~ ~ ~'C'fIUS93104287 02,~
generall~T be understood as a sphrical embodiment of the above-described embodiment of Figs. 3 thru I~VO 93/21859 PCT/US93/04287 21~~~8Q
houiever, in wM ch the construction thereof is accomplished by means of a plurality of concentric, As may be noted b~~ the Let~t~ers A and B in Fig. 1, each of said tubule,''~ay be divided into two or more segments to p3~o,v~ide for varying types of polypeptides. The embodiment of Figs. 21 and 22 will, accordingly, operate, as a practical matter, in the same fashion as the "jelly roll"
embodiment of Figs. 3.to 5.
The embodiment of Figs. 21 and 22 is also closely related in structure in the embodiment of Figs. 1'7 and 18.
Accordingly, while there has been shown and described the preferred embodiment of the instant invention it may be appreciated that the invention ma3~ be embodied otherwise than is herein specifically shown and described and that within said emhodi-ment, certain changes may be made within the forms and arrangements of the parts without departing from the underlying ideas or principles of this invention within the scope of Claims appended herewith.
SYSTEM
BACKGROUND OF THE INVEi~'TION
Biodegradable materials have been known in W~ 93/21859 PCT/U~93/04287 °'"''' ~~.3~~~0 SUMMARI OF THE TNVENTrON
A ssrstem 'for tissue-specific deliverz-of therapeutic agents includes ~an imp l.antable element biodegradable in situ within human tissue; a vasoinducti~~e agent integrated into a surface of tha element; and having the therapeutic 'agents incorporated into the implantable element.
Upan implanta ion of the implantable element ,into tissue, the vasoinductive agent stimulates capillary growth, facilitating delivery of the therapeutic agents to the selected tissue.
More, particularl~T, the present invention provides for a biodegradable substrate upon which is-applied a bioactive or pharmakinetic agent. Where a p?urality of different agents are employed,'the various agents are,applied in a matrix-like fashion upon the substrate: The ~:;- ~~ ~ substrate' is then rolled about a' major or time axis 'thereof such that, in a rro s-section taken . r. ~ ...,X
~ r .n N ,rf.. .....T. I . . T
-r: r .t. a., m. ~ , c~ ,cor..c :y .,.r .~ .
....f v, n,:nr;, ,P:Y"i... 'd'u~
.. , .. r.. -y> ~. v,,~3' .
..,...,..,.x':,.. n. f . ~. i> '5~.9.r. ..f , ~'.~' n~ . J. .., :... . , .. . , l.. .t~...
' 'f . M ~.1.~ . 1 .
,...i..;~.... ...~....a..i::,...,..W.r...~fl..f>.,,.:,.!tf..
~%~:~.....TT?~?t,.,....~fi~I:.rv....fa..:=.!!i'.La,R,.K.n..,::1~~,..x1x_....n., _ >,..n:at...v..tv~.re,.l.'Br9.rk~a..o ......,..,. ...........,...x.
N'~ 93/21859 ~ ~ ~ ~ ~ 1'CT/U~93104287 ..,,> _ radially from said axis, there may be defined a spiral cross-section. Upon the surface o.f the rolled substrate is applied-a vascular It is yet another object of the invention to provide a biodegradable implant for delivery of pharmakinetic agents, comprising:
(a) a therapeutically effective amount of a vasoinductive agent;
(b) in physical communication with said vasoinductive agent, a biodegradable element having affixed thereto at least one pharmakinetic agent, said biodegradable element comprising a series of radially concentric shells having respectively different pharmakinetic agents, or respectively different combinations of said pharmakinetic agents, disposed upon each of said respective, radially concentric shells such that the outermost shell and its associated agents will be delivered earliest while the innermost shell and its corresponding agents will be delivered last to a human tissue of interest, whereby, upon implantation of said biodegradable implant into said human tissue, said vasoinductive agent will stimulate capillary growth to thereby facilitate delivery of said pharmakinetic agents as a function of the rate of in vivo dissolution of said biodegradable element within said human tissue.
The above and yet other objects and advantages of the present invention will become apparent from the hereinafter set forth Brief Description of the Drawings, Detailed Description of the Invention and Claims appended herewith.
,:
y r ..~ . ~~..:
v .r ,. r ., k , a_ ., s .c- .~ ~ ' ~.
,,; ~,. z .. ~ , _ _.
." A
.. ~..5 .~
n: ,~w ~.. ~~ .. ° ~.
.. , ~ ~ . , .. '' .. ~ , :'" . . .. . .. ,.. . , .. W' . , :..::s... . ... ..,.~.~~T.., ~''.'~'s's'~' ,'_~~s~:~c. ~..~?,.~";x~'~..v~-..,...,~ ~V0 93/21859 PCT/tJ~93144Z~7 Fig. 6 is a cross-sectional view taken ai.ong Line 6-6 of Fig. 5.
WO 93/21859 PCTlUS93l04287 ....
Figs. l3 and l4 are views similarl~° to Fig.
'l but shok=inj other embodiments thereof.
i DETAILED DESCRIPTION OF THE INVENTION
With reference to Fig. 1 there is shown, in front perspective view, a patient 10 having scalp 20 in which have been placed incisions 12, preparatory to a hair implant procedure.
Fig. 2 is a top view of the patient 10 of Fig. 1 showing, between incisions 12, various types of hair implantation structures 14 and 16.
Such structures 14 and 16 may comprise hair follicles taken from other areas of the patient's own scalp (known as homographs), may comprise a synthetically created hair implant or may comprise a combination of homographs and synthetically created hair implants.
The insertion of the inventive biodegradable timed release implants 18 between such hair structures or normally occurring or thinning hair follicles, acts to provide required nutrition, WO 93/2859 PC~'/US931U4287 X134680 ..
i~
including amino acids; hormones o_r~drugs such 1W0 93/2159 PCT/US93/~42~7 would be particular pol~~peptides. Different poly-peptides correspond to different stakes of the i~0 93/21859 FCT/US93l04287 ~~~4sg~
spiral sl.rtacture, while the ~ele~en-related pol.~=-W~ ~3/21i359 PLTlUS~3/042~7 ..
ls' For example, it may be desirable to release the pharmakinetic agent during the categen phase -.,.~ VfO 93/2~8~9 PCT/US931442~7 '' 2~.34~8~
substrate 28 of implant 18 may also be varied.
For example, as is shown in the side cross-sectional 'riew of Fig. 7, if one wishes to increase the duration of deli~~ery of a bioactive agent 130 relative to the duration during which am agent. 131 is delivered, end 132 of substrate 128 mad= be thic'hened while end I,34 may be made narrower, this meaning that agent. 130 would be released more 'sl owl~~ into the del iverv site, while went 13I would be del ivered more quickl3:
Should''one wish tQ achieve: the reverse effect, a~ structure of the t~pe showy in Fig . 8 would 1?e 'used in which edge 232 of biodegradable substrate 228 would be narrowed while edge 234 of-thP sub-strafe ~ao.uld be thickened, thereby providing' for faster deliVer~',of agent 230 at the beginning of the biodegrading of the implant and a sl.o~aer deliver~T of agent 231 toward the end of the action of the implant.
m. ~ ;
,~ ~ : ~.
.~ . ~ .,, . .,:- ., :, ::.~
..T ,.:'9 . ~. .T
J t'...' f,'.
t ~t ., ,~~'y,:~( . rh T .gym...
. ...,1.
k~ r r.t~ .~ .'j'"L
~.i i .
. ,1'. .
~n~,., n .,. Y (~
x .
!-irv.!'~, yf',~. w ~.~~' .' 7 t , t~'., E..:
.~ . H'~~., ~ n J, t ~ .:r r' ... r ., .. fi .J- ~"~x,~, .~L.n, f . ~. c'Y
.r v. A
a ,.r ~ '~33..
.e;,: z .
,t~ ~ 3~3'..
: ,~: .
F .: .:~' , . ~ ,:.
.. a ..
:, .
x .. . ..
s. , f . N ,~
t : a #
: _ , nEJ
: ~:r ~~r 'a . r:
.
s - ::~if .. r JS
." , ~ r ..,ust. r.x.:..r..
a>T .~.
s~:-'~.
P i..
r. :,Jt:
.fit ...t.
7:....."t~
. 1.~Y7f m1 my~%~
.~u .~ a ~ .,..Td,n.-.;
n,.;.:, , , , ~ r ., i~ .
. , ,r".
, ,is .
. . . , ..r....
~_c"..:......,....
. n....t;:.i..r._.,.
,.Al<....rr~.,.>.._;1.3..v,..rl;>r.r..,.,.",....e~.".:.,~..._...>a:..~:...~.~', ,.,fr...._._.~:.-~,ti'....>;~~.,._..~,....fi,~sra..a.~~.r~:~',r~..s~:...,~s.".r.~...r....f.-i.,~.Aa.Yn.:'~'~n_i_._......
........__.........., 1~0 93/2859 PCT/US93/04287 . .
d It is noted that the rate of~...'dissolution of respective areas of substFa~te 28 may also be regulated by varying the~internal binding ,.-~~,. 1V~ 93/21859 PCflU~s93104287 structure. This provision of vasoinductive agent.
13~ alonj the time axis of the structure will '~~.3 4~~~
where a plurality of different pharmakinetic ~, VVO 9312 D X59 ~ ~ ~ ~ ~ ~ ~ ~'C'fIUS93104287 02,~
generall~T be understood as a sphrical embodiment of the above-described embodiment of Figs. 3 thru I~VO 93/21859 PCT/US93/04287 21~~~8Q
houiever, in wM ch the construction thereof is accomplished by means of a plurality of concentric, As may be noted b~~ the Let~t~ers A and B in Fig. 1, each of said tubule,''~ay be divided into two or more segments to p3~o,v~ide for varying types of polypeptides. The embodiment of Figs. 21 and 22 will, accordingly, operate, as a practical matter, in the same fashion as the "jelly roll"
embodiment of Figs. 3.to 5.
The embodiment of Figs. 21 and 22 is also closely related in structure in the embodiment of Figs. 1'7 and 18.
Accordingly, while there has been shown and described the preferred embodiment of the instant invention it may be appreciated that the invention ma3~ be embodied otherwise than is herein specifically shown and described and that within said emhodi-ment, certain changes may be made within the forms and arrangements of the parts without departing from the underlying ideas or principles of this invention within the scope of Claims appended herewith.
Claims (7)
1. A biodegradable implant for delivery of pharmakinetic agents, comprising:
(a) a therapeutically effective amount of a vasoinductive agent;
(b) in physical communication with said vasoinductive agent, a biodegradable element having affixed thereto at least one pharmakinetic agent, said biodegradable element comprising a series of radially concentric shells having respectively different pharmakinetic agents, or respectively different combinations of said pharmakinetic agents, disposed upon each of said respective, radially concentric shells such that the outermost shell and its associated agents will be delivered earliest while the innermost shell and its corresponding agents will be delivered last to a human tissue of interest, whereby, upon implantation of said biodegradable implant into said human tissue, said vasoinductive agent will stimulate capillary growth to thereby facilitate delivery of said pharmakinetic agents as a function of the rate of in vivo dissolution of said biodegradable element within said human tissue.
(a) a therapeutically effective amount of a vasoinductive agent;
(b) in physical communication with said vasoinductive agent, a biodegradable element having affixed thereto at least one pharmakinetic agent, said biodegradable element comprising a series of radially concentric shells having respectively different pharmakinetic agents, or respectively different combinations of said pharmakinetic agents, disposed upon each of said respective, radially concentric shells such that the outermost shell and its associated agents will be delivered earliest while the innermost shell and its corresponding agents will be delivered last to a human tissue of interest, whereby, upon implantation of said biodegradable implant into said human tissue, said vasoinductive agent will stimulate capillary growth to thereby facilitate delivery of said pharmakinetic agents as a function of the rate of in vivo dissolution of said biodegradable element within said human tissue.
2. The biodegradable implant as recited in claim 1 further comprising: vasoinductive agent disposed between each of said concentric shells.
3. The biodegradable implant as recited in claim 1, in which said biodegradable element comprises a material selected from the group consisting essentially of:
processed sheep dermal collagen, Hench's bioglass, fibrinogens, polyiminocarbonates, and polylactic acid.
processed sheep dermal collagen, Hench's bioglass, fibrinogens, polyiminocarbonates, and polylactic acid.
4. The biodegradable implant as recited in claim 1 in which said vasoinductive agent comprises an angiogenic agent.
5. The biodegradable implant as recited in claim 1, in which said vaso-inductive agent comprises:
a growth factor selected from the group consisting essentially of a vascular endothelial growth factor, platelet growth factor, vascular permeability factor, fibroblast growth factor, and transforming growth factor beta.
a growth factor selected from the group consisting essentially of a vascular endothelial growth factor, platelet growth factor, vascular permeability factor, fibroblast growth factor, and transforming growth factor beta.
6. The biodegradable implant as recited in claim 1 in which said therapeutic agent is selected from the group consisting essentially of:
chemotherapeutics, analgesics, hormones, enzymes, catalysts, anesthetics, anti-inflammatories, antibiotics, immuno-globulins and free-radical scavengers.
chemotherapeutics, analgesics, hormones, enzymes, catalysts, anesthetics, anti-inflammatories, antibiotics, immuno-globulins and free-radical scavengers.
7. The biodegradable implant as recited in claim 1, in which said concentric shells comprise concentric tubules.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US876,783 | 1992-04-30 | ||
| US07/876,783 US5326568A (en) | 1991-05-03 | 1992-04-30 | Method of tissue-specific delivery |
| PCT/US1993/004287 WO1993021859A1 (en) | 1992-04-30 | 1993-04-26 | Tissue-specific implantable therapeutic agent delivery system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2134680A1 CA2134680A1 (en) | 1993-11-11 |
| CA2134680C true CA2134680C (en) | 2004-11-30 |
Family
ID=25368571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002134680A Expired - Fee Related CA2134680C (en) | 1992-04-30 | 1993-04-26 | Tissue-specific implantable therapeutic agent delivery system |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US5326568A (en) |
| EP (1) | EP0637946A4 (en) |
| JP (1) | JPH08500088A (en) |
| AU (1) | AU4370593A (en) |
| CA (1) | CA2134680C (en) |
| WO (1) | WO1993021859A1 (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5651976A (en) * | 1993-06-17 | 1997-07-29 | The United States Of America As Represented By The Secretary Of The Navy | Controlled release of active agents using inorganic tubules |
| JPH08503715A (en) * | 1993-09-24 | 1996-04-23 | バクスター、インターナショナル、インコーポレイテッド | Method for promoting vascularization of implantable devices |
| JP4259610B2 (en) * | 1994-04-08 | 2009-04-30 | キューエルティー・ユーエスエイ・インコーポレーテッド | Liquid delivery composition |
| US6911216B1 (en) | 1994-10-12 | 2005-06-28 | Genzyme Corporation | Targeted delivery via biodegradable polymers |
| US5782789A (en) * | 1994-10-19 | 1998-07-21 | Atrium Medical Corporation | Macrochannel phosthetic/delivery patch |
| US5660848A (en) * | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
| FI954565A0 (en) | 1995-09-27 | 1995-09-27 | Biocon Oy | Biologically applied polymeric material to the implant and foil preparation |
| US5869041A (en) * | 1996-01-12 | 1999-02-09 | The Miriam Hospital | Delivery of bioactive compounds to an organism |
| US20080305999A1 (en) * | 1996-11-01 | 2008-12-11 | John Francis Martin | Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia |
| WO1998020027A2 (en) * | 1996-11-01 | 1998-05-14 | Eurogene Limited | Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device |
| US6203813B1 (en) | 1997-01-13 | 2001-03-20 | Lance L. Gooberman | Pharmaceutical delivery device and method of preparation therefor |
| US6263880B1 (en) | 1998-06-22 | 2001-07-24 | Neovasys, Inc. | Method of enhancing blood flow in tissue |
| US6921412B1 (en) | 1999-05-18 | 2005-07-26 | Cryolife, Inc. | Self-supporting, shaped, three-dimensional biopolymeric materials and methods |
| EP1185312B1 (en) * | 1999-05-27 | 2005-03-23 | Monsanto Company | Biomaterials modified with superoxide dismutase mimics |
| US7039863B1 (en) | 1999-07-23 | 2006-05-02 | Adobe Systems Incorporated | Computer generation of documents using layout elements and content elements |
| US6618698B1 (en) * | 1999-08-12 | 2003-09-09 | Quickturn Design Systems, Inc. | Clustered processors in an emulation engine |
| AU2001297782B2 (en) * | 2000-11-07 | 2006-03-02 | Cryolife, Inc. | Expandable foam-like biomaterials and methods |
| US8539334B2 (en) * | 2000-12-27 | 2013-09-17 | Tractmanager, Inc. | Document management system having automatic notifications |
| US10114821B2 (en) * | 2000-12-27 | 2018-10-30 | Tractmanager, Inc. | Method and system to access to electronic business documents |
| US7968119B2 (en) * | 2001-06-26 | 2011-06-28 | Farrell John J | Tamper-proof narcotic delivery system |
| FR2839645B1 (en) * | 2002-05-15 | 2005-08-05 | Backert Marie Elisabeth Cuine | MULTILAMELLAR SYSTEM FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES (IN PARTICULAR DRUGS) BY ORAL INGESTION |
| NZ541580A (en) | 2002-12-30 | 2009-03-31 | Thomson Corp | Knowledge-management systems for law firms |
| DE10361940A1 (en) * | 2003-12-24 | 2005-07-28 | Restate Patent Ag | Degradation control of biodegradable implants by coating |
| US7716206B2 (en) * | 2004-11-01 | 2010-05-11 | At&T Intellectual Property I, L.P. | Communication networks and methods and computer program products for performing searches thereon while maintaining user privacy |
| US8234137B2 (en) * | 2005-10-03 | 2012-07-31 | Stellar Services | One view integrated project management system |
| US20080059494A1 (en) * | 2006-09-01 | 2008-03-06 | Ean Rouse Schuessler | Document database system and method |
| US20080183766A1 (en) * | 2007-01-31 | 2008-07-31 | Weston David W | Methods and systems for inductive data transformation |
| US8024315B2 (en) * | 2007-07-20 | 2011-09-20 | International Business Machines Corporation | Method of dynamically providing a compound object's source information during its development |
| US8316314B2 (en) | 2010-06-30 | 2012-11-20 | Thermo Electron Scientific Instruments Llc | Intelligent multi-functional macros language for analytical measurements |
| US10420923B1 (en) | 2010-08-10 | 2019-09-24 | Amiram Katz | Method and device for intrathecal administering of immunoglobulin |
| US10817508B2 (en) * | 2010-12-13 | 2020-10-27 | Micro Focus Llc | Techniques for constructing and editing a search query using an overload cell |
| US8551525B2 (en) | 2010-12-23 | 2013-10-08 | Biostructures, Llc | Bone graft materials and methods |
| US20150066556A1 (en) * | 2013-08-29 | 2015-03-05 | Steve Dominick | System and method for an electronic document management and review tool for litigation matters |
| CN103593447B (en) * | 2013-11-18 | 2017-02-08 | 北京国双科技有限公司 | Data processing method and device applied to database table |
| US20150363887A1 (en) * | 2014-06-11 | 2015-12-17 | Joe Ferri | System for tracking and attributing credit accrued through geographically dispersed representation |
| US9808608B2 (en) * | 2014-11-16 | 2017-11-07 | International Business Machines Corporation | Helical coil delivery device for active agent |
| WO2017009965A1 (en) * | 2015-07-15 | 2017-01-19 | 三菱電機株式会社 | Display control device and display control method |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| CA1045977A (en) * | 1973-05-17 | 1979-01-09 | Arthur D. Little | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
| US4939689A (en) * | 1987-04-09 | 1990-07-03 | Crowninshield Software, Inc. | Outline-driven database editing and retrieval system |
| US4952403A (en) * | 1987-06-19 | 1990-08-28 | President And Fellows Of Harvard College | Implants for the promotion of healing of meniscal tissue |
| WO1991017744A1 (en) * | 1990-05-14 | 1991-11-28 | Jernberg Gary R | Surgical implant and method incorporating chemotherapeutic agents |
| EP0463194A1 (en) * | 1990-06-23 | 1992-01-02 | Boehringer Ingelheim Kg | Process for the preparation of poly(D,L-lactide) and its use as a drug carrier |
| US6178413B1 (en) * | 1998-05-20 | 2001-01-23 | Technolines, Llc | Database program with automatic creation of user features |
| US6182069B1 (en) * | 1992-11-09 | 2001-01-30 | International Business Machines Corporation | Video query system and method |
| US5428735A (en) * | 1992-12-28 | 1995-06-27 | International Business Machines Corporation | Method and apparatus for maintaining a record of set-creating data processing activities and associated data sets |
| US5649182A (en) * | 1995-03-17 | 1997-07-15 | Reitz; Carl A. | Apparatus and method for organizing timeline data |
| US5787418A (en) * | 1996-09-03 | 1998-07-28 | International Business Machine Corporation | Find assistant for creating database queries |
| US5924089A (en) * | 1996-09-03 | 1999-07-13 | International Business Machines Corporation | Natural language translation of an SQL query |
| US6067568A (en) * | 1996-12-10 | 2000-05-23 | International Business Machines Corporation | Automatic setup of services for computer system users |
| FI106990B (en) * | 1996-12-31 | 2001-05-15 | Nokia Mobile Phones Ltd | A method of transmitting information to a user |
| KR19980076633A (en) * | 1997-04-11 | 1998-11-16 | 윤종용 | Information retrieval apparatus and method in mobile information terminal |
-
1992
- 1992-04-30 US US07/876,783 patent/US5326568A/en not_active Expired - Fee Related
-
1993
- 1993-04-26 CA CA002134680A patent/CA2134680C/en not_active Expired - Fee Related
- 1993-04-26 AU AU43705/93A patent/AU4370593A/en not_active Abandoned
- 1993-04-26 EP EP93913809A patent/EP0637946A4/en not_active Withdrawn
- 1993-04-26 JP JP5519630A patent/JPH08500088A/en active Pending
- 1993-04-26 WO PCT/US1993/004287 patent/WO1993021859A1/en not_active Application Discontinuation
- 1993-06-28 US US08/082,419 patent/US5494677A/en not_active Expired - Fee Related
-
2000
- 2000-10-31 US US09/703,482 patent/US7031960B1/en not_active Ceased
-
2007
- 2007-12-27 US US11/965,372 patent/USRE43391E1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2134680A1 (en) | 1993-11-11 |
| EP0637946A4 (en) | 1996-09-11 |
| EP0637946A1 (en) | 1995-02-15 |
| AU4370593A (en) | 1993-11-29 |
| WO1993021859A1 (en) | 1993-11-11 |
| USRE43391E1 (en) | 2012-05-15 |
| US7031960B1 (en) | 2006-04-18 |
| US5326568A (en) | 1994-07-05 |
| JPH08500088A (en) | 1996-01-09 |
| US5494677A (en) | 1996-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2134680C (en) | Tissue-specific implantable therapeutic agent delivery system | |
| US10028837B2 (en) | Delivery system attachment | |
| CN109259897B (en) | Bone implant with mesh | |
| DE60133278T2 (en) | DEVICE FOR TREATING HEART DISEASES | |
| DE69935716T2 (en) | STENT WITH SMOOTH ENDS | |
| US7238199B2 (en) | Method and apparatus for stent deployment with enhanced delivery of bioactive agents | |
| JP4245845B2 (en) | Device to fix tissue regeneration scaffold for cartilage repair | |
| DE60003580T2 (en) | MEDICAL DEVICE with synthetic surface containing nucleic acid for in vivo induction of its endothelialization | |
| EP2033667A3 (en) | Porous medicated stent | |
| CN110418615A (en) | Implantation material with curved bone contact element | |
| US20030078659A1 (en) | Graft element | |
| US5653760A (en) | Method and apparatus for managing macromolecular distribution | |
| JP2019022651A (en) | Bone implant for enclosing bone material | |
| WO1999008728A1 (en) | Composition and device for in vivo cartilage repair | |
| JP2003508185A (en) | Implantable controlled release device | |
| AU2005265145A2 (en) | Encapsulated or coated stent systems | |
| WO1992022332A3 (en) | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology | |
| CN103705278A (en) | Surgical implant and applicator | |
| US5580569A (en) | Article for tissue-specific delivery of therapeutic agents | |
| WO2002074192A2 (en) | Methods and devices for occluding myocardial holes | |
| US20130304032A1 (en) | Bone fixation system with structure to enhance tissue growth and/or administer medicament inside bone | |
| US20100057114A1 (en) | PEEK Spinal Mesh and PEEK Spinal Mesh Applicator | |
| US20100035324A1 (en) | Apparatus for the regeneration of human tissue | |
| EP2254649B1 (en) | Delivery system attachment | |
| CN115989006A (en) | Adjustable bone implant for encapsulating bone material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |